Combination of gemcitabine with cisplatin in the treatment of advanced or metastatic transitional cell carcinoma of urinary tract (report of 18 cases)
- VernacularTitle:吉西他滨联合顺铂方案治疗晚期尿路上皮移行细胞癌18例报告
- Author:
Dingwei YE
;
Bo DAI
;
Yinzhong FANG
;
Jiangshan YING
;
Hailiang ZHANG
- Publication Type:Journal Article
- Keywords:
Transitional cell carcinoma;
Urinary tract neoplasms;
Gemcitabine;
Cisplatin;
Combined chemotherapy
- From:
Chinese Journal of Urology
2000;0(05):-
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo evaluate the therapeutic effect and toxicities of gemcitabine combined with cisplatin in the treatment of advanced or metastatic transitional cell carcinoma (TCC) of urinary tract. Methods Eighteen patients with advanced or metastatic TCC of urinary tract (15 cases of bladder TCC,2 of renal pelvic TCC,and 1 of ureteral TCC),who were pathologically confirmed,were treated with GC regimen (gemcitabine 1000 mg/m 2,iv infusion on day 1 and day 8;cisplatin 30 mg/m 2,iv infusion on day 2,day 8 and day 9).Before treatment, Karnofsy score for each patient was evaluated with a result of ≥60;liver and renal functions and blood routine test were normal.GC regimen was repeated for 2-3 cycles every 3-4 weeks and the response rate was evaluated.ResultsThree patients (16.7%) had complete response; 7(38.9%), partial response;5(27.8%),no response;and 3(16.7%) had progression.The overall response rate was 55.6%. The main toxic effects included decrease in white cell count (10 cases),anemia (7),nausea and vomiting (10) and constipation (8),which were mild or moderate and disappeared after stopping treatment.No chemotherapy-associated death occurred.ConclusionsGemcitabine combined with cisplatin in the treatment of advanced or metastatic transitional cell carcinoma of urinary tract is effective,and the toxicity is mild and tolerated. It is suggested that GC regimen can be used as the first line chemotherapy.
